Vascular Endothelial Growth Factor +936C/T and +405G/C Polymorphisms and Cancer Risk: a Meta-analysis

Cao, Chao; Jingjing, Fang; Ying, Tao; Sun, Shifang; Lv, Dan; Chen, Zhong-Bo; Ma, Hongying; Yu, Yiming; Ding, Qunli; Shu, Lihua; Deng, Zaichun

doi:10.1016/j.arcmed.2010.09.006

Cited by 21 publications

(15 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous metaanalyses performed by Xu et al, 35 Hong et al, 36 and Liu et al 37 contained one study related to OC; those by Cao et al 38 and Hong et al 39 included 2 studies that tested OC. None of these 5 meta-analyses focused exclusively on OC, and none of them conducted subgroup analysis for OC.…”

Section: Discussionmentioning

confidence: 99%

Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, −460C > T, and −2578C > A) and Their Susceptibility to Ovarian Cancer

Zhang

Qin

Qin³

2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, −460C > T, and −2578C > A) and Their Susceptibility to Ovarian Cancer

Zhang

Qin

Qin³

2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…VEGF and related proteins are critical for development, growth and metastasis of tumors, and their expression levels have been demonstrated to be predictive of resistance to treatment 30-32. Genetic polymorphisms in the promoter region, 5'UTR, and 3'UTR of the VEGF gene are associated with VEGF levels in plasma or tumors, and therefore can be diagnostic, prognostic, and predictive biomarkers for patients with tumors 20-23.…”

Section: Discussionmentioning

confidence: 99%

“…The genotypes of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen, were evaluated 16, since clinical reports suggested that their genetic variations have the potential to influence the expression of VEGF, and thereby the growth of tumors, metastatic spread, and response to treatment 20-23; however, they failed to predict the response 16. Obviously, the final goal of cancer chemotherapy is an improvement in long-term survival, not a short-term clinical response, so parameters predicting prognosis have been absolutely imperative.…”

Section: Introductionmentioning

confidence: 99%

VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma

Tamura¹,

Kuwahara²,

Yamamori³

et al. 2012

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Reports have been accumulating that genetic properties are predictive of clinical response after and/or toxicity during cancer chemotherapy, but little information is available concerning effects on long-term survival. In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival.Methods: A course consisted of the continuous infusion of 5-FU at 400 mg/m2/day for days 1-5 and 8-12, the infusion of CDDP at 40 mg/m2/day on days 1 and 8, and radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with a second course repeated after a 2-week interval. The VEGF genotypes -1498T/C, -1154G/A, -634C/G, -7C/T, 936C/T, and 1612G/A were evaluated.Results: The complete response (CR) rate was 46.9% (23/49). The 5-year survival rate was 42.9 % (21/49). There were 7 patients with a CR, but survival of less than 5 years. They died from myocardial infarction (N=1), sudden cardiac death after suffering from heart failure (N=1), acute myeloid leukemia that developed from myelodysplastic syndromes (N=1), factors not specified (N=2), oropharynx cancer (N=1), and tongue cancer (N=1). VEGF -634C/G had no effect on clinical response, but long-term survival depended on the genotype (p=0.033, Fisher's; p=0.038, Cochran-Armitage; p=0.079, Log-rank). The genotype frequency of 7 patients with a CR, but survival of less than 5 years was different from that for the other 42 patients (p=0.032, Fisher's). None of the other 5 genotypes evaluated affected either clinical response or survival.Conclusions: VEGF -634C/G is possibly predictive of long-term survival after treatment with a definitive 5-FU/CDDP-based CRT. Further clinical studies with a larger number of cases are needed to clarify the effects of this genotype.

show abstract

“…Kaplan-Meier mortality curves were created to exhibit differences in mortality by selected risk factors. Quantitative synthesis of all relevant studies was performed and the methods used have been described in detail in previous studies (16,17). The HRs of time-to-event data were directly extracted from the original study or were read off survival curves to estimate the logHR and its variance, as suggested by Parmar et al (18).…”

Section: Methodsmentioning

confidence: 99%

C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease

Deng

Zhao

Cao

et al. 2013

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

The present study aimed to evaluate whether circulating C-reactive protein (CRP) levels are a biomarker of systemic inflammation and a significant predictor of future chronic obstructive pulmonary disease (COPD) outcome. During the study, 116 patients with stable COPD and 35 age- and gender-matched healthy subjects with normal pulmonary function were observed. Patient follow-up was also performed to evaluate the strength of the associations between CRP levels and future outcomes. The observations from the present study showed that serum CRP levels were significantly higher in stable COPD patients than in control subjects (4.48±0.83 vs. 1.01±0.27 mg/l, respectively; P<0.05). In addition, it was identified that a serum CRP concentration of >3 mg/l is a poor prognostic variable of COPD compared with a CRP concentration of ≤3 mg/l [hazard ratio (HR), 2.71; 95% confidence interval (CI), 1.05–6.99; P<0.05]. A quantitative synthesis of four studies including 1,750 COPD patients was performed and statistically similar results were obtained (HR, 1.54; 95% CI, 1.14–2.07; P<0.01). The present study showed that circulating CRP levels are higher in stable COPD patients and, therefore, may be used as a long-term predictor of future outcomes. These observations highlight the importance of high sensitivity CRP assays in patients with stable COPD.

show abstract

Vascular Endothelial Growth Factor +936C/T and +405G/C Polymorphisms and Cancer Risk: a Meta-analysis

Cited by 21 publications

References 54 publications

Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, −460C > T, and −2578C > A) and Their Susceptibility to Ovarian Cancer

Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, −460C > T, and −2578C > A) and Their Susceptibility to Ovarian Cancer

VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma

C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease

Contact Info

Product

Resources

About